Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

30.14B

Market cap30.14B

Price-Earnings ratio

37.20

Price-Earnings ratio37.20

Dividend yield

—

Dividend yield—

Average volume

3.11M

Average volume3.11M

High today

$218.62

High today$218.62

Low today

$210.49

Low today$210.49

Open price

$216.83

Open price$216.83

Volume

904.58K

Volume904.58K

52 Week high

$495.55

52 Week high$495.55

52 Week low

$197.81

52 Week low$197.81

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $217.02, giving the company a market capitalization of 30.14B. It carries a P/E multiple of 37.20.

On 2026-08-07, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $210.49 to $218.62. With shares now at $217.02, the stock is trading +3.1% above its intraday low and -0.7% below the session's peak.

Trading volume for Alnylam Pharmaceuticals(ALNY) stock has reached 904.58K, versus its average volume of 3.11M.

The stock's 52-week range extends from a low of $197.81 to a high of $495.55.

ALNY News

Simply Wall St 1d

Alnylam Pharmaceuticals On Lowered TTR Guidance And What It Means For Valuation - simplywall.st

...

TipRanks 3d

Alnylam price target lowered to $455 from $485 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $455 from $485 and keeps a Buy rating on the shares. Following the $200M midpoint reduction...

Simply Wall St 3d

Alnylam Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story?

In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, marking a shift from a loss...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More ALNY News

The Motley Fool 4d

Alnylam Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Josh Brodsky Chief Executive O...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Netflix

Novo Nordisk

Eli Lilly

Vertex Pharmaceuticals

Oracle

Salesforce

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.